Anti hmgcr

Manufactured by Merck Group

Anti-HMGCR is a laboratory reagent used for the detection and quantification of the HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) protein. HMGCR is an enzyme involved in the cholesterol biosynthesis pathway. Anti-HMGCR can be used in various analytical techniques, such as Western blotting, ELISA, and immunohistochemistry, to measure the levels of HMGCR in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

HMGCR (2 citations) Anti-HMGCR (MABS1233) (2 citations)

2 protocols using anti hmgcr

Analyzing Cellular Protein Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell lysates were analyzed via 10% and 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to polyvinylidenedifluoride membranes (Millipore, Billerica, MA) following standard methods. Blots were incubated at 4 °C overnight with the following primary antibodies: anti-UQCRB (Sigma-Aldrich, Saint Louis, MO), anti-HMGCR (Millipore), anti-MVD (Abcam, Cambridge, MA), anti-LSS (Abcam, Cambridge, MA), and β-actin (Abcam, Cambridge, MA). Immunolabeling was performed using Clarity Western ECL substrate (Bio-rad, Hercules, CA). Images were quantified using Image Lab^TM software (Bio-rad).

Kim J.E., Hong J.W., Lee H.S., Kim W., Lim J., Cho Y.S, & Kwon H.J. (2018). Hsa-miR-10a-5p downregulation in mutant UQCRB-expressing cells promotes the cholesterol biosynthesis pathway. Scientific Reports, 8, 12407.

+ Open protocol

+ Expand

Cholesterol Regulation Pathway Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Simvastatin, lovastatin, fluvastatin, 25-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, GW3965, farnesyl pyrophosphate and geranylgeranyl pyrophosphate were purchased from Sigma-Aldrich. Primary antibodies: anti-β-actin (Sigma-Aldrich, A2228), anti-SREBP-2 (Abcam, ab30682), anti-SREBP-1 (Santa Cruz Biotechnology, sc-8984), anti-HMGCR (Millipore, 07-572), and anti-PARP (Cell Signaling, 46D11). Secondary antibodies were purchased from Li-Cor Biosciences. Low-density lipoprotein (LDL) and lipoprotein-deficient serum (LPDS) were purchased from Biomedical Technologies, Inc.

Casella C., Miller D.H., Lynch K, & Brodsky A.S. (2014). Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells. Gynecologic oncology, 135(2), 333-341.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!